Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment

Background: Progressive multifocal leukoencephalopathy (PML) caused by the JC virus is the main limitation to the use of disease modifying therapies for treatment of multiple sclerosis (MS). Methods: To assess the PML risk in course of ocrelizumab, urine and blood samples were collected from 42 MS p...

Descripción completa

Detalles Bibliográficos
Autores principales: Prezioso, Carla, Grimaldi, Alfonso, Landi, Doriana, Nicoletti, Carolina Gabri, Brazzini, Gabriele, Piacentini, Francesca, Passerini, Sara, Limongi, Dolores, Ciotti, Marco, Palamara, Anna Teresa, Marfia, Girolama Alessandra, Pietropaolo, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473394/
https://www.ncbi.nlm.nih.gov/pubmed/34578264
http://dx.doi.org/10.3390/v13091684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473394/
https://www.ncbi.nlm.nih.gov/pubmed/34578264
http://dx.doi.org/10.3390/v13091684

Ejemplares similares